These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 18196620

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 24. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
    Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F, ECLIPSE Study Investigators.
    Cardiology; 2008 Sep; 111(4):219-28. PubMed ID: 18434729
    [Abstract] [Full Text] [Related]

  • 26. [Efficacy and safety comparison of different statins in elderly patients].
    Chen Y, Jiang C, Liu M, Liu F, Fan Y.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Nov; 42(11):910-5. PubMed ID: 25620252
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
    Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C, Donahue S.
    Clin Cardiol; 2014 Oct; 37(10):597-604. PubMed ID: 25269777
    [Abstract] [Full Text] [Related]

  • 29. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 32. Achieving lipid goals in real life: the Dutch DISCOVERY study.
    Bots AF, Kastelein JJ, Discovery Netherlands Investigators.
    Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
    Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG.
    Am J Cardiol; 2003 Jan 01; 91(1):33-41. PubMed ID: 12505568
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism.
    Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, Manabe I, Lee SH.
    J Cardiovasc Pharmacol Ther; 2010 Jun 01; 15(2):167-74. PubMed ID: 20147603
    [Abstract] [Full Text] [Related]

  • 38. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
    Wlodarczyk J, Sullivan D, Smith M.
    Am J Cardiol; 2008 Dec 15; 102(12):1654-62. PubMed ID: 19064019
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
    Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E, HeFH Study Group.
    Am J Cardiol; 2003 Dec 01; 92(11):1287-93. PubMed ID: 14636905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.